Pharma main Lupin on Wednesday grew to become the newest firm to launch its model of the antiviral drug favipiravir to deal with COVID-19. The drugmaker knowledgeable the exchanges about the identical in a submitting. ” Lipin today announced the launch of its Favipiravir in India under the brand name Covihalt for the treatment of mild to moderate COVID-19. Favipiravir has received authorization from the Drug Controller General of India (DCGI) for emergency use,” the corporate mentioned in a submitting.
A slew of generic drug producers together with Cipla Ltd, Sun Pharma and Hetero Labs have been growing favipiravir. Lupin’s model, Covihalt shall be accessible as 200 mg tablets within the type of a strip of 10 tablets, and priced at Rs 49 per pill, the corporate mentioned.
Sun Pharma on Tuesday, launched its personal model, at Rs 35, to date the most affordable in India.
Lupin’s shares nevertheless witnessed little change because the inventory was up a marginal 0.03 per cent at 12:35 pm on Wednesday.